TrialJournal of hematology & oncology2016

A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients.

Cinzia Pellegrini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.